Iron Deficiency in Long-Term Parenteral Nutrition Therapy

Yi L. Hwa, Shahrooz Rashtak, Darlene G. Kelly, Joseph A Murray

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Iron is not routinely added to parenteral nutrition (PN) formulations in the United States because of the risk of anaphylaxis and concerns about incompatibilities. Studies have shown that iron dextran in non-lipid-containing PN solutions is safe. Data are limited on iron status, prevalence of iron deficiency anemia (IDA), and efficacy of intravenous iron infusion in long-term home PN (HPN). We aimed to determine the incidence of IDA and to examine the effectiveness of parenteral iron replacement in patients receiving HPN. Methods: Medical records of patients receiving HPN at the Mayo Clinic from 1977 to 2010 were reviewed. Diagnoses, time to IDA development, and hemoglobin, ferritin, and mean corpuscular volume (MCV) values were extracted. Response of iron indices to intravenous iron replacement was investigated. Results: Of 185 patients (122 women), 60 (32.4%) were iron deficient. Five patients were iron deficient, and 18 had unknown iron status before HPN. Of 93 patients who had sufficient iron storage, 37 had IDA development after a mean of 27.2 months (range, 2-149 months) of therapy. Iron was replaced by adding maintenance iron dextran to PN or by therapeutic iron infusion. Patients with both replacement methods had significant improvement in iron status. With intravenous iron replacement, mean ferritin increased from 10.9 to 107.6 mcg/L (P <.0001); mean hemoglobin increased from 11.0 to 12.5 g/dL (P =.0001); and mean MCV increased from 84.5 to 89.0 fL (P =.007). Conclusions: Patients receiving HPN are susceptible to IDA. Iron supplementation should be addressed for patients who rely on PN.

Original languageEnglish (US)
Pages (from-to)869-876
Number of pages8
JournalJournal of Parenteral and Enteral Nutrition
Volume40
Issue number6
DOIs
StatePublished - Aug 1 2016

Fingerprint

Nutrition Therapy
Parenteral Nutrition
Iron
Iron-Deficiency Anemias
Erythrocyte Indices
Ferritins
Dextrans
Hemoglobins
Parenteral Nutrition Solutions
Home Parenteral Nutrition

Keywords

  • dysmotility
  • fistulae
  • home parenteral nutrition
  • intravenous iron replacement
  • iron deficiency anemia
  • short bowel syndrome
  • small bowel obstruction

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Iron Deficiency in Long-Term Parenteral Nutrition Therapy. / Hwa, Yi L.; Rashtak, Shahrooz; Kelly, Darlene G.; Murray, Joseph A.

In: Journal of Parenteral and Enteral Nutrition, Vol. 40, No. 6, 01.08.2016, p. 869-876.

Research output: Contribution to journalArticle

Hwa, Yi L. ; Rashtak, Shahrooz ; Kelly, Darlene G. ; Murray, Joseph A. / Iron Deficiency in Long-Term Parenteral Nutrition Therapy. In: Journal of Parenteral and Enteral Nutrition. 2016 ; Vol. 40, No. 6. pp. 869-876.
@article{697836d183c74a27bc8275073f7e5342,
title = "Iron Deficiency in Long-Term Parenteral Nutrition Therapy",
abstract = "Background: Iron is not routinely added to parenteral nutrition (PN) formulations in the United States because of the risk of anaphylaxis and concerns about incompatibilities. Studies have shown that iron dextran in non-lipid-containing PN solutions is safe. Data are limited on iron status, prevalence of iron deficiency anemia (IDA), and efficacy of intravenous iron infusion in long-term home PN (HPN). We aimed to determine the incidence of IDA and to examine the effectiveness of parenteral iron replacement in patients receiving HPN. Methods: Medical records of patients receiving HPN at the Mayo Clinic from 1977 to 2010 were reviewed. Diagnoses, time to IDA development, and hemoglobin, ferritin, and mean corpuscular volume (MCV) values were extracted. Response of iron indices to intravenous iron replacement was investigated. Results: Of 185 patients (122 women), 60 (32.4{\%}) were iron deficient. Five patients were iron deficient, and 18 had unknown iron status before HPN. Of 93 patients who had sufficient iron storage, 37 had IDA development after a mean of 27.2 months (range, 2-149 months) of therapy. Iron was replaced by adding maintenance iron dextran to PN or by therapeutic iron infusion. Patients with both replacement methods had significant improvement in iron status. With intravenous iron replacement, mean ferritin increased from 10.9 to 107.6 mcg/L (P <.0001); mean hemoglobin increased from 11.0 to 12.5 g/dL (P =.0001); and mean MCV increased from 84.5 to 89.0 fL (P =.007). Conclusions: Patients receiving HPN are susceptible to IDA. Iron supplementation should be addressed for patients who rely on PN.",
keywords = "dysmotility, fistulae, home parenteral nutrition, intravenous iron replacement, iron deficiency anemia, short bowel syndrome, small bowel obstruction",
author = "Hwa, {Yi L.} and Shahrooz Rashtak and Kelly, {Darlene G.} and Murray, {Joseph A}",
year = "2016",
month = "8",
day = "1",
doi = "10.1177/0148607115587329",
language = "English (US)",
volume = "40",
pages = "869--876",
journal = "Journal of Parenteral and Enteral Nutrition",
issn = "0148-6071",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Iron Deficiency in Long-Term Parenteral Nutrition Therapy

AU - Hwa, Yi L.

AU - Rashtak, Shahrooz

AU - Kelly, Darlene G.

AU - Murray, Joseph A

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: Iron is not routinely added to parenteral nutrition (PN) formulations in the United States because of the risk of anaphylaxis and concerns about incompatibilities. Studies have shown that iron dextran in non-lipid-containing PN solutions is safe. Data are limited on iron status, prevalence of iron deficiency anemia (IDA), and efficacy of intravenous iron infusion in long-term home PN (HPN). We aimed to determine the incidence of IDA and to examine the effectiveness of parenteral iron replacement in patients receiving HPN. Methods: Medical records of patients receiving HPN at the Mayo Clinic from 1977 to 2010 were reviewed. Diagnoses, time to IDA development, and hemoglobin, ferritin, and mean corpuscular volume (MCV) values were extracted. Response of iron indices to intravenous iron replacement was investigated. Results: Of 185 patients (122 women), 60 (32.4%) were iron deficient. Five patients were iron deficient, and 18 had unknown iron status before HPN. Of 93 patients who had sufficient iron storage, 37 had IDA development after a mean of 27.2 months (range, 2-149 months) of therapy. Iron was replaced by adding maintenance iron dextran to PN or by therapeutic iron infusion. Patients with both replacement methods had significant improvement in iron status. With intravenous iron replacement, mean ferritin increased from 10.9 to 107.6 mcg/L (P <.0001); mean hemoglobin increased from 11.0 to 12.5 g/dL (P =.0001); and mean MCV increased from 84.5 to 89.0 fL (P =.007). Conclusions: Patients receiving HPN are susceptible to IDA. Iron supplementation should be addressed for patients who rely on PN.

AB - Background: Iron is not routinely added to parenteral nutrition (PN) formulations in the United States because of the risk of anaphylaxis and concerns about incompatibilities. Studies have shown that iron dextran in non-lipid-containing PN solutions is safe. Data are limited on iron status, prevalence of iron deficiency anemia (IDA), and efficacy of intravenous iron infusion in long-term home PN (HPN). We aimed to determine the incidence of IDA and to examine the effectiveness of parenteral iron replacement in patients receiving HPN. Methods: Medical records of patients receiving HPN at the Mayo Clinic from 1977 to 2010 were reviewed. Diagnoses, time to IDA development, and hemoglobin, ferritin, and mean corpuscular volume (MCV) values were extracted. Response of iron indices to intravenous iron replacement was investigated. Results: Of 185 patients (122 women), 60 (32.4%) were iron deficient. Five patients were iron deficient, and 18 had unknown iron status before HPN. Of 93 patients who had sufficient iron storage, 37 had IDA development after a mean of 27.2 months (range, 2-149 months) of therapy. Iron was replaced by adding maintenance iron dextran to PN or by therapeutic iron infusion. Patients with both replacement methods had significant improvement in iron status. With intravenous iron replacement, mean ferritin increased from 10.9 to 107.6 mcg/L (P <.0001); mean hemoglobin increased from 11.0 to 12.5 g/dL (P =.0001); and mean MCV increased from 84.5 to 89.0 fL (P =.007). Conclusions: Patients receiving HPN are susceptible to IDA. Iron supplementation should be addressed for patients who rely on PN.

KW - dysmotility

KW - fistulae

KW - home parenteral nutrition

KW - intravenous iron replacement

KW - iron deficiency anemia

KW - short bowel syndrome

KW - small bowel obstruction

UR - http://www.scopus.com/inward/record.url?scp=84978975566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978975566&partnerID=8YFLogxK

U2 - 10.1177/0148607115587329

DO - 10.1177/0148607115587329

M3 - Article

C2 - 25972429

AN - SCOPUS:84978975566

VL - 40

SP - 869

EP - 876

JO - Journal of Parenteral and Enteral Nutrition

JF - Journal of Parenteral and Enteral Nutrition

SN - 0148-6071

IS - 6

ER -